JP2008526715A - 神経精神障害の治療のためのアリールピペラジン誘導体 - Google Patents

神経精神障害の治療のためのアリールピペラジン誘導体 Download PDF

Info

Publication number
JP2008526715A
JP2008526715A JP2007548841A JP2007548841A JP2008526715A JP 2008526715 A JP2008526715 A JP 2008526715A JP 2007548841 A JP2007548841 A JP 2007548841A JP 2007548841 A JP2007548841 A JP 2007548841A JP 2008526715 A JP2008526715 A JP 2008526715A
Authority
JP
Japan
Prior art keywords
alkyl
butyl
piperazin
cycloalkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007548841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526715A5 (enExample
Inventor
カンピアーニ、ジュセッペ
ブティーニ、ステファニア
ファットルッソ、カテリーナ
トロッタ、フランチェスコ
フランチェスキーニ、シルビア
アンジェリス、メリ デ
ニールセン、カリン、サンダガー
Original Assignee
ユニベルシタ デグリ ストゥディ ディ シエナ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニベルシタ デグリ ストゥディ ディ シエナ filed Critical ユニベルシタ デグリ ストゥディ ディ シエナ
Publication of JP2008526715A publication Critical patent/JP2008526715A/ja
Publication of JP2008526715A5 publication Critical patent/JP2008526715A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
JP2007548841A 2005-01-03 2006-01-02 神経精神障害の治療のためのアリールピペラジン誘導体 Pending JP2008526715A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200500004 2005-01-03
US64100605P 2005-01-04 2005-01-04
PCT/EP2006/050001 WO2006072608A2 (en) 2005-01-03 2006-01-02 Aryl piperazine derivatives for the treatment of neuropsychiatric disorders

Publications (2)

Publication Number Publication Date
JP2008526715A true JP2008526715A (ja) 2008-07-24
JP2008526715A5 JP2008526715A5 (enExample) 2009-02-19

Family

ID=36600734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007548841A Pending JP2008526715A (ja) 2005-01-03 2006-01-02 神経精神障害の治療のためのアリールピペラジン誘導体

Country Status (7)

Country Link
US (1) US20090238761A1 (enExample)
EP (1) EP1836192A2 (enExample)
JP (1) JP2008526715A (enExample)
AU (1) AU2006204522A1 (enExample)
CA (1) CA2593266A1 (enExample)
NZ (1) NZ555491A (enExample)
WO (1) WO2006072608A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536921A (ja) * 2012-10-11 2015-12-24 サザン リサーチ インスティテュート アミノアルキルピペラジンの尿素及びアミド誘導体並びにその使用
JP2016516829A (ja) * 2013-04-23 2016-06-09 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ピラジノ［１，２−ａ］インドール化合物、その調製および医薬としての使用
JP2017537938A (ja) * 2014-12-17 2017-12-21 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニＡｚｉｅｎｄｅ Ｃｈｉｍｉｃｈｅ Ｒｉｕｎｉｔｅ Ａｎｇｅｌｉｎｉ Ｆｒａｎｃｅｓｃｏ Ａ．Ｃ．Ｒ．Ａ．Ｆ．Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 新しい抗菌性化合物
JP2018150349A (ja) * 2012-05-09 2018-09-27 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ヘテロアリール化合物及びその使用方法
JPWO2018168738A1 (ja) * 2017-03-13 2019-11-21 大日本住友製薬株式会社 ２，６−ジ置換ピリジン誘導体
JP2020509088A (ja) * 2017-02-24 2020-03-26 深▲チェン▼市霊蘭生物医薬科技有限公司Ｓｈｅｎｚｈｅｎ Ｌｉｎｇｌａｎ Ｂｉｏ−Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ 新規なドーパミンｄ３受容体選択的リガンド及びびその調製方法並びに医薬使用

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903986A1 (fr) * 2006-07-21 2008-01-25 Pierre Fabre Medicament Sa Nouveaux derives chromenes ou thiochromenes carboxamides, leur procede de preparation et leurs applications en therapeutique
GB0615809D0 (en) * 2006-08-09 2006-09-20 Istituto Di Ricerche D Biolog Therapeutic compounds
CA2672920A1 (en) * 2006-10-13 2008-04-17 Universita'degli Studi Di Siena Aryl piperazine derivatives useful for the treatment of neuropsychiatric disorders
EP2114948B1 (en) * 2006-12-28 2014-06-25 AbbVie Inc. Inhibitors of poly(adp-ribose)polymerase
AU2007354861B2 (en) * 2007-06-15 2013-03-21 The United States Of America As Represented By The Secretary, Department Of Health And Human Services 4-phenylpiperazine derivatives with functionalized linkers as dopamine D3 receptor selective ligands and methods of use
US20110002855A1 (en) * 2007-06-25 2011-01-06 Neurogen Corporation Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
EP2238125A1 (en) * 2008-02-01 2010-10-13 NeuroSearch A/S Novel aryl piperazine derivatives useful as modulators of dopamine and serotonin receptors
WO2010040808A1 (en) * 2008-10-10 2010-04-15 Neurosearch A/S Novel quinolinylamide derivatives useful as modulators of dopamine and serotonin receptors
BR112014022780A8 (pt) 2012-03-16 2021-06-15 Vitae Pharmaceuticals Inc composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso
EP2825541B1 (en) 2012-03-16 2016-06-22 Vitae Pharmaceuticals, Inc. Liver x receptor modulators
WO2015014256A1 (en) 2013-07-29 2015-02-05 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use thereof
EP3083589B1 (en) 2013-12-20 2019-12-18 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use thereof
WO2016115039A1 (en) 2015-01-12 2016-07-21 Reviva Pharmaceuticals Inc. Methods for treating pulmonary hypertension
HK1244449A1 (zh) * 2015-01-12 2018-08-10 雷维瓦药品公司 用於治疗与帕金森病相关联的精神病的方法
HK1245081A1 (zh) * 2015-01-12 2018-08-24 雷维瓦药品公司 用於治疗阿尔茨海默病的方法
WO2016192657A1 (en) 2015-06-03 2016-12-08 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use and use thereof
HUE051898T2 (hu) 2015-06-17 2021-03-29 Pfizer Triciklusos vegyületek és alkalmazásuk foszfodiészteráz inhibitorokként
US11299476B2 (en) 2016-03-14 2022-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof
HUE055634T2 (hu) 2016-03-14 2021-12-28 The United States Of America As Represented By Dopamin D3 receptor szelektív antagonisták/részleges antagonisták; eljárás azok elõállítására; és alkalmazásuk
GB201704325D0 (en) * 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds
US11337971B2 (en) 2018-09-11 2022-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine D3 receptor selective antagonists/partial agonists and uses thereof
CA3186583A1 (en) 2020-06-11 2021-12-16 Chdi Foundation, Inc. Heterocyclic compounds and imaging agents for imaging huntingtin protein

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2777849A (en) * 1954-07-23 1957-01-15 American Cyanamid Co 1, 1'-alkylenedipiperazines and methods of preparing same
US2837522A (en) * 1955-10-20 1958-06-03 American Cyanamid Co Substituted alkylenedipiperazines
US3646047A (en) * 1970-02-02 1972-02-29 American Cyanamid Co Certain benzo(b)thiophene-2-carboxamide derivatives
US3734915A (en) * 1970-02-02 1973-05-22 American Cyanamid Co N-(-(4-phenyl-1-piperazinyl)alkyl)benzo(b)thiophene or benzofuran-2-carboxamides
JPS4942683A (enExample) * 1972-06-02 1974-04-22
JPH0352877A (ja) * 1989-07-18 1991-03-07 Basf Ag アミノアルキル置換２―アミノチアゾール―誘導体
JPH03291275A (ja) * 1989-12-20 1991-12-20 Adir 新規の（１−ナフチル）ピペラジン誘導体、その製造方法およびそれを含有する薬剤組成物
JPH04321677A (ja) * 1991-01-24 1992-11-11 Fab Espanola De Prod Quimicos I Farmaceut Sa 新規の２−メトキシフェニルピペラジン誘導体
WO1996002246A1 (de) * 1994-07-15 1996-02-01 Basf Aktiengesellschaft Verwendung heterocyclischer verbindungen als dopamin-d3 liganden
JPH11263773A (ja) * 1997-12-12 1999-09-28 Toyama Chem Co Ltd アルキルエーテル誘導体またはその塩並びにそれらを含有するカルシウム拮抗剤
US6100255A (en) * 1998-10-28 2000-08-08 Neurogen Corporation 3-aminoalkylamino-2H-1,4-benzoxazines and 3-aminoalkylamino-2H-1,4-benzothiazines: dopamine receptor subtype specific ligands
WO2001049677A1 (en) * 1999-12-30 2001-07-12 H. Lundbeck A/S Phenylpiperazinyl derivatives
JP2002532481A (ja) * 1998-12-17 2002-10-02 アメリカン・ホーム・プロダクツ・コーポレイション ５−ｈｔ１ａ受容体活性を有するピペラジンエチルアミド誘導体
WO2003028728A1 (en) * 2001-09-28 2003-04-10 Richter Gedeon Vegyészeti Gyár Rt. 4-(4-substituted piperazinyl-1yl)-butylcarboxamides as d3 dopamine subtype selective ligands
WO2004004729A1 (de) * 2002-07-04 2004-01-15 Schwarz Pharma Ag Heteroarencarboxamide zur verwendung als dopamin-d3 liganden zur behandlung von zns-erkrankungen
WO2004033426A2 (de) * 2002-10-07 2004-04-22 Proteosys Ag Heteroarylpropyl-piperazine und heteroarylpropyl-piperidine als dopaminerge und serotoninerge agenzien
WO2004112729A2 (en) * 2003-06-19 2004-12-29 Psychiatric Genomics, Inc. Dual function compounds and uses thereof
WO2006058993A1 (fr) * 2004-12-01 2006-06-08 Bioprojet Derives d’arylpiperazine et leur utilisation comme ligands selectifs du recepteur d3 de la dopamine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803203A (en) * 1986-11-05 1989-02-07 Warner-Lambert Company Phenyl and heterocyclic piperazinyl alkoxy-benzheterocyclic compounds as antipsychotic agents
US4954502A (en) * 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
GB9306578D0 (en) * 1993-03-30 1993-05-26 Merck Sharp & Dohme Therapeutic agents
CA2498936C (en) 2002-09-14 2013-02-12 Gov't Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services Structurally rigid dopamine d3 receptor selective ligands and process for making them

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2777849A (en) * 1954-07-23 1957-01-15 American Cyanamid Co 1, 1'-alkylenedipiperazines and methods of preparing same
US2837522A (en) * 1955-10-20 1958-06-03 American Cyanamid Co Substituted alkylenedipiperazines
US3646047A (en) * 1970-02-02 1972-02-29 American Cyanamid Co Certain benzo(b)thiophene-2-carboxamide derivatives
US3734915A (en) * 1970-02-02 1973-05-22 American Cyanamid Co N-(-(4-phenyl-1-piperazinyl)alkyl)benzo(b)thiophene or benzofuran-2-carboxamides
JPS4942683A (enExample) * 1972-06-02 1974-04-22
JPH0352877A (ja) * 1989-07-18 1991-03-07 Basf Ag アミノアルキル置換２―アミノチアゾール―誘導体
JPH03291275A (ja) * 1989-12-20 1991-12-20 Adir 新規の（１−ナフチル）ピペラジン誘導体、その製造方法およびそれを含有する薬剤組成物
JPH04321677A (ja) * 1991-01-24 1992-11-11 Fab Espanola De Prod Quimicos I Farmaceut Sa 新規の２−メトキシフェニルピペラジン誘導体
WO1996002246A1 (de) * 1994-07-15 1996-02-01 Basf Aktiengesellschaft Verwendung heterocyclischer verbindungen als dopamin-d3 liganden
JPH11263773A (ja) * 1997-12-12 1999-09-28 Toyama Chem Co Ltd アルキルエーテル誘導体またはその塩並びにそれらを含有するカルシウム拮抗剤
US6100255A (en) * 1998-10-28 2000-08-08 Neurogen Corporation 3-aminoalkylamino-2H-1,4-benzoxazines and 3-aminoalkylamino-2H-1,4-benzothiazines: dopamine receptor subtype specific ligands
JP2002532481A (ja) * 1998-12-17 2002-10-02 アメリカン・ホーム・プロダクツ・コーポレイション ５−ｈｔ１ａ受容体活性を有するピペラジンエチルアミド誘導体
WO2001049677A1 (en) * 1999-12-30 2001-07-12 H. Lundbeck A/S Phenylpiperazinyl derivatives
WO2003028728A1 (en) * 2001-09-28 2003-04-10 Richter Gedeon Vegyészeti Gyár Rt. 4-(4-substituted piperazinyl-1yl)-butylcarboxamides as d3 dopamine subtype selective ligands
WO2004004729A1 (de) * 2002-07-04 2004-01-15 Schwarz Pharma Ag Heteroarencarboxamide zur verwendung als dopamin-d3 liganden zur behandlung von zns-erkrankungen
WO2004033426A2 (de) * 2002-10-07 2004-04-22 Proteosys Ag Heteroarylpropyl-piperazine und heteroarylpropyl-piperidine als dopaminerge und serotoninerge agenzien
WO2004112729A2 (en) * 2003-06-19 2004-12-29 Psychiatric Genomics, Inc. Dual function compounds and uses thereof
WO2006058993A1 (fr) * 2004-12-01 2006-06-08 Bioprojet Derives d’arylpiperazine et leur utilisation comme ligands selectifs du recepteur d3 de la dopamine

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018150349A (ja) * 2012-05-09 2018-09-27 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ヘテロアリール化合物及びその使用方法
JP2015536921A (ja) * 2012-10-11 2015-12-24 サザン リサーチ インスティテュート アミノアルキルピペラジンの尿素及びアミド誘導体並びにその使用
JP2016516829A (ja) * 2013-04-23 2016-06-09 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ピラジノ［１，２−ａ］インドール化合物、その調製および医薬としての使用
JP2017537938A (ja) * 2014-12-17 2017-12-21 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニＡｚｉｅｎｄｅ Ｃｈｉｍｉｃｈｅ Ｒｉｕｎｉｔｅ Ａｎｇｅｌｉｎｉ Ｆｒａｎｃｅｓｃｏ Ａ．Ｃ．Ｒ．Ａ．Ｆ．Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 新しい抗菌性化合物
JP2020509088A (ja) * 2017-02-24 2020-03-26 深▲チェン▼市霊蘭生物医薬科技有限公司Ｓｈｅｎｚｈｅｎ Ｌｉｎｇｌａｎ Ｂｉｏ−Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ 新規なドーパミンｄ３受容体選択的リガンド及びびその調製方法並びに医薬使用
JP7017797B2 (ja) 2017-02-24 2022-02-09 深▲チェン▼市霊蘭生物医薬科技有限公司 新規なドーパミンｄ３受容体選択的リガンド及びびその調製方法並びに医薬使用
JPWO2018168738A1 (ja) * 2017-03-13 2019-11-21 大日本住友製薬株式会社 ２，６−ジ置換ピリジン誘導体

Also Published As

Publication number Publication date
CA2593266A1 (en) 2006-07-13
AU2006204522A1 (en) 2006-07-13
US20090238761A1 (en) 2009-09-24
WO2006072608A3 (en) 2006-09-28
WO2006072608A2 (en) 2006-07-13
NZ555491A (en) 2010-01-29
EP1836192A2 (en) 2007-09-26

Similar Documents

Publication Publication Date Title
JP2008526715A (ja) 神経精神障害の治療のためのアリールピペラジン誘導体
DE69315920T2 (de) Kondensierte heterozyklische Verbindungen, deren Herstellung und Verwendung
KR101287955B1 (ko) 지방산 아미드 하이드롤라제의 조정자로서 피페라지닐 및피페리디닐 우레아
US5532243A (en) Antipsychotic nitrogen-containing bicyclic compounds
DE60212841T2 (de) 4 piperazinylindolderivate mit affinität zum 5-ht6-rezeptor
JP4865221B2 (ja) 新規化合物とそれらの使用
TWI237023B (en) Benzoxazinone derivatives, their preparation and use
JP6458028B2 (ja) インドール及びピロールの新規な誘導体、その製造方法及びそれを含む医薬組成物
JPH04506071A (ja) 中枢神経系活性を有する複素環系アミン
JP2004532834A (ja) ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用
JP2009298819A (ja) スルホンアミド誘導体類と、その製造方法及び医薬としての応用
JPWO1993009116A1 (ja) キヌクリジン化合物およびその医薬用途
IL109234A (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
JP2006502985A (ja) ムスカリン性受容体拮抗剤として有用な３，６−二置換アザビシクロ［３．１．０］ヘキサン誘導体
KR100729536B1 (ko) 4-페닐-1-피페라지닐,-피페리디닐 및 -테트라히드로피리딜유도체
TWI526434B (zh) 雜環化合物
JP2006514978A (ja) ムスカリン受容体アンタゴニストである置換アザビシクロヘキサン誘導体
JP2010504367A (ja) 性機能障害、認知障害、精神病性障害、不安、鬱病などを処置するための５ｈｔ１ａ受容体モジュレーターとしての５−｛２−［４−（２−メチル−５−キノリニル）−ｌ−ピペリジニル］エチル｝キノリノン誘導体
MXPA02006498A (es) Novedosos derivados de indol.
BG108531A (bg) Нови х...'...роарилни производни, 'яхно'о пол"-аван... и използван...
US20060047114A1 (en) Azabicyclic amine histamine-3 receptor antagonists
CN101137645A (zh) 用于治疗神经精神病障碍的芳基哌嗪衍生物
US20110059019A1 (en) Novel aryl piperazine derivatives useful as modulators of dopamine and serotonin receptors
JP4831903B2 (ja) 新規化合物、その使用および製造
ZA200309258B (en) 4-Piperazinylindole derivatives with 5-HT6 receptor affinity.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110816

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110817

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120127